Imagine every pill you take comes with an invisible digital passport that proves it's genuine — from the factory floor to your pharmacy shelf. PharmaLedger built a shared, tamper-proof digital ledger (think of it like a Google Doc that nobody can secretly edit) connecting pharmaceutical companies, hospitals, and patients. It tracks medicines to catch counterfeits, makes clinical trial enrollment faster, and lets health data be shared securely without anyone losing control of their information. Eleven major pharma companies actually helped build and test it, so this isn't theory — it was designed with the industry sitting at the table.
Counterfeit medicines kill hundreds of thousands of people annually and cost the pharmaceutical industry billions. At the same time, clinical trials are painfully slow to recruit patients, and health data sits locked in silos because no one trusts the sharing mechanisms. These problems persist because the healthcare industry lacks a shared, tamper-proof digital infrastructure that all parties — manufacturers, regulators, hospitals, patients — can trust equally.
The project delivered a blockchain-based platform with 30 deliverables, including first and final reference implementations of a governance user interface. Core capabilities cover end-to-end pharmaceutical product tracking, clinical trial recruitment and submission tools, and machine-learning health data marketplace components — all built as open-source reference implementations.
If you are a pharmaceutical manufacturer dealing with counterfeit medicines entering your supply chain — this project developed a blockchain-based end-to-end product tracking system validated with 11 large pharma companies across 13 countries. It provides a tamper-proof record from production to patient, reducing counterfeiting risk and meeting serialization regulations.
If you are a clinical research organization struggling with slow patient recruitment and complex regulatory submissions — this project built a blockchain-enabled platform tested by leading clinical trials companies from the 30-partner consortium. It streamlines recruitment workflows and submission processes while maintaining full data integrity across trial sites.
If you are a health data company trying to enable secure data sharing between hospitals without violating privacy rules — this project created machine-learning health data marketplace tools with built-in governance, backed by reference implementations. The open-source approach means you can integrate it into existing hospital systems without vendor lock-in.
The project produced open-source reference implementations, which means the core software is freely available. Implementation costs would depend on integration with your existing systems, infrastructure setup, and customization. With 30 deliverables produced, there is substantial documentation to reduce onboarding effort.
The platform was designed and validated with 11 large pharmaceutical companies across 13 countries, suggesting it was built for enterprise-scale operations. The architecture uses decentralized governance specifically to support wide adoption across the healthcare ecosystem. Based on available project data, the consortium included supply chain partners who tested real-world scenarios.
PharmaLedger explicitly committed to open-source reference implementation as part of its design. However, specific licensing terms for individual components may vary across the 30-partner consortium. Contact the coordinator at Universidad Politécnica de Madrid for detailed IP and licensing information.
The project objective explicitly states the platform was designed for compliance with extant and emerging standards and regulation. Given the involvement of 11 large pharma companies — who face strict regulatory scrutiny — regulatory alignment was a core design requirement, not an afterthought.
The platform was built for end-to-end connectivity and interoperability with existing systems. Two reference implementations of the governance user interface were delivered (first and final versions), providing ready-to-use starting points. Based on available project data, the 3-year project timeline produced 30 deliverables covering integration methodology.
The project closed in December 2022, but the platform was designed with sustainability in mind by leveraging existing blockchain technologies and open-source code. The project website (pharmaledger.eu) and the large consortium of 19 industry partners suggest continued community support. Contact the coordinator for current maintenance status.
This is a heavyweight consortium with serious commercial intent: 19 out of 30 partners are from industry (63%), including 11 large pharmaceutical companies — a concentration of major pharma players rarely seen in a single EU project. The 6 SMEs bring specialized blockchain, security, and business intelligence expertise. Universities and research institutes (7 partners) cover pharmacoeconomics, patient requirements, big data, and electronic health records. Spanning 13 countries (including non-EU participants from Switzerland, Israel, UK, and US), this consortium mirrors the global nature of pharmaceutical supply chains. The presence of supply chain partners, clinical trials companies, patient representatives, and healthcare service providers means the full value chain was represented — from drug manufacturing to patient delivery.
Universidad Politécnica de Madrid (Spain) — search for PharmaLedger project coordinator contact via the project website
Want to connect with the PharmaLedger team or explore how blockchain can secure your pharmaceutical supply chain? SciTransfer can arrange a direct introduction to the right consortium partner for your needs.
